Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy - 15/10/16
Doi : 10.1016/j.jaad.2016.06.062
Courtney B. Rubin, MD a, b, Rosalie Elenitsas, MD c, Laura Taylor, MD d, Simon F. Lacey, PhD e, Irina Kulikovskaya, MSc, MB(ASCP)CM e, Minnal Gupta, MSc e, Jan J. Melenhorst, PhD d, Alison Loren, MD, MS e, f, Noelle Frey, MD, MSCE e, f, Carl H. June, MD d, e, David Porter, MD e, f, Misha Rosenbach, MD c, ⁎ 
a Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
b Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
d Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
e Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
f Division of Hematology and Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
∗Correspondence to: Misha Rosenbach, MD, Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, 2 Maloney Building, Philadelphia, Pennsylvania 19104Department of DermatologyUniversity of Pennsylvania3600 Spruce Street, 2 Maloney BuildingPhiladelphiaPennsylvania19104
| Funding sources: None. |
|
| Disclosures: Dr Rosalie Elenitsas receives royalties as book editor for Lippincott and honoraria for her role as a consultant for Myriad Genetics. Dr Noelle Frey serves as an investigator for Novartis and has received grant funding from Novartis. Research performed by the lab of Dr Melenhorst is supported by Novartis. CTL019 in an investigational drug in phase 1 trials that was developed in the lab of Dr Carl June. It has been licensed by Novartis from the University of Pennsylvania. Novartis provides financial support for the clinical trial. Dr June has IP ownership that is licensed by Penn. Dr Simon Lacey is an investigator for Novartis as has received grant funding from Novartis. Dr David Porter has received research support, royalties, and IP interest from Novartis. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 75 - N° 5
P. 1054-1057 - novembre 2016 Retour au numéro
Article précédent
- Interleukin-12 immunohistochemistry as a diagnostic tool for patch-stage mycosis fungoides
- David M. Lemchak, Oleg E. Akilov
- A cross-sectional study of trends in the stage of melanoma at diagnosis in the United States from 2001-2011
- Giselle Prado, Peter D'Amore, Adam Tagliero, Mercedes Florez-White, Juan Acuna
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?